Vertex Pharmaceuticals: R&D Portfolio Management (A)

Below are the available bulk discount rates for each individual item when you purchase a certain amount

Register as a Premium Educator at, plan a course, and save your students up to 50% with your academic discount.

Publication Date:
June 10, 2004

Professional Services

Harvard Business School

Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will select two drug candidates from its internal research portfolio of four projects to develop on its own, without the help of strategic partners. CEO Joshua Boger and President Vicki Sato are grappling with which two projects to select. Focuses on how to select projects and how to manage the process of portfolio selection.

Copyright © 2021 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.

Vertex Pharmaceuticals: R&D Portfolio Management (A)

Research & References of Vertex Pharmaceuticals: R&D Portfolio Management (A)|A&C Accounting And Services

Leave a Reply